Candidiasis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 135 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Candidiasis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Candidiasis - Pipeline Review, H1 2015', provides an overview of the Candidiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Candidiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Candidiasis Overview 11
Therapeutics Development 12
Pipeline Products for Candidiasis - Overview 12
Pipeline Products for Candidiasis - Comparative Analysis 13
Candidiasis - Therapeutics under Development by Companies 14
Candidiasis - Therapeutics under Investigation by Universities/Institutes 17
Candidiasis - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Candidiasis - Products under Development by Companies 22
Candidiasis - Products under Investigation by Universities/Institutes 25
Candidiasis - Companies Involved in Therapeutics Development 26
Actavis plc 26
Aureogen Biosciences, Inc. 27
Basilea Pharmaceutica AG 28
Biomar Microbial Technologies 29
Cellceutix Corporation 30
Eisai Co., Ltd. 31
General Biologicals Corporation 32
Grupo Ferrer Internacional, S.A. 33
iCo Therapeutics Inc. 34
Novabiotics Ltd 35
NovaDigm Therapeutics, Inc. 36
Novartis AG 37
Onxeo SA 38
Panacela Labs, Inc. 39
Scynexis, Inc. 40
Sealife PHARMA GMBH 41
Sequella, Inc. 42
Viamet Pharmaceuticals, Inc. 43
Wellstat Vaccines, LLC 44
Candidiasis - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
AC-17 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
albaconazole - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
amphotericin b - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
arasertaconazole - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AUGC-10 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AUGC-15 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
candida vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
candidiasis vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
E-1210 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
E-1211 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
isavuconazonium sulfate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
miconazole - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
mutanobactins - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NDV-3 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NDV-3A - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NP-339 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PAC-113 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pegylated amphotericin B - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PEV-7 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
PMX-1408 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PMX-1502 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PMX-1570 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PMX-1576 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PMX-1591 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PMX-1625 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PMX-30016 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PMX-519 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Prof-002 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
SCY-078 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SLP-0901 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SLP-0904 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecule for Candidiasis - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule for Candidiasis - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecule for Candidiasis and Cryptococcosis - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule for Cryptococcosis and Candidiasis - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule for Fungal Infections - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules for Candidiasis - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules for Candidiasis - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules for Fungal Infections - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
SQ-109 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
VT-1161 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
XELRYX-3 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Candidiasis - Recent Pipeline Updates 108
Candidiasis - Dormant Projects 122
Candidiasis - Discontinued Products 125
Candidiasis - Product Development Milestones 126
Featured News & Press Releases 126
Nov 03, 2014: Basilea Reports Granting Of U.S. Orphan Drug Designation To Isavuconazole For The Treatment Of Invasive Candidiasis 126
Oct 16, 2014: Basilea Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study 126
Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 127
Jul 16, 2014: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis 128
Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 128
Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig 129
Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 130
Nov 18, 2013: Cellceutix Identifies PMX-1408 as treatment Gram-Negative and Candida Fungal Infections 130
Nov 18, 2013: Cellceutix Identifies Drug Candidate for Candida Fungal Infections 131
Sep 26, 2013: NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis 132
Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 135
Disclaimer 135

List of Tables
Number of Products under Development for Candidiasis, H1 2015 12
Number of Products under Development for Candidiasis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Late Stage Development, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Comparative Analysis by Unknown Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Candidiasis - Pipeline by Actavis plc, H1 2015 26
Candidiasis - Pipeline by Aureogen Biosciences, Inc., H1 2015 27
Candidiasis - Pipeline by Basilea Pharmaceutica AG, H1 2015 28
Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2015 29
Candidiasis - Pipeline by Cellceutix Corporation, H1 2015 30
Candidiasis - Pipeline by Eisai Co., Ltd., H1 2015 31
Candidiasis - Pipeline by General Biologicals Corporation, H1 2015 32
Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 33
Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2015 34
Candidiasis - Pipeline by Novabiotics Ltd, H1 2015 35
Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2015 36
Candidiasis - Pipeline by Novartis AG, H1 2015 37
Candidiasis - Pipeline by Onxeo SA, H1 2015 38
Candidiasis - Pipeline by Panacela Labs, Inc., H1 2015 39
Candidiasis - Pipeline by Scynexis, Inc., H1 2015 40
Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2015 41
Candidiasis - Pipeline by Sequella, Inc., H1 2015 42
Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2015 43
Candidiasis - Pipeline by Wellstat Vaccines, LLC, H1 2015 44
Assessment by Monotherapy Products, H1 2015 45
Number of Products by Stage and Target, H1 2015 47
Number of Products by Stage and Mechanism of Action, H1 2015 49
Number of Products by Stage and Route of Administration, H1 2015 51
Number of Products by Stage and Molecule Type, H1 2015 53
Candidiasis Therapeutics - Recent Pipeline Updates, H1 2015 108
Candidiasis - Dormant Projects, H1 2015 122
Candidiasis - Dormant Projects (Contd..1), H1 2015 123
Candidiasis - Dormant Projects (Contd..2), H1 2015 124
Candidiasis - Discontinued Products, H1 2015 125